NASDAQ:RVPHW Reviva Pharmaceuticals (RVPHW) Stock Price, News & Analysis $0.17 -0.02 (-10.47%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends About Reviva Pharmaceuticals Stock (NASDAQ:RVPHW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Reviva Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.09▼$0.2952-Week Range$0.07▼$1.62Volume400 shsAverage Volume16,455 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewReviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.Read More… Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Receive RVPHW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVPHW Stock News HeadlinesReviva announces enrollment update for OLE study of brilaroxazineNovember 13, 2024 | markets.businessinsider.comReviva Pharmaceuticals Progresses with Brilaroxazine Study UpdateNovember 13, 2024 | markets.businessinsider.comTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.November 20, 2024 | Angel Publishing (Ad)Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Quotes, Forecast and News SummaryOctober 15, 2024 | benzinga.comReviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: AnalystOctober 7, 2024 | benzinga.comEF Hutton Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy RecommendationSeptember 24, 2024 | msn.comRVPH: RECOVER Biomarker KOL EventSeptember 16, 2024 | msn.comSee More Headlines RVPHW Stock Analysis - Frequently Asked Questions How have RVPHW shares performed this year? Reviva Pharmaceuticals' stock was trading at $1.43 on January 1st, 2024. Since then, RVPHW stock has decreased by 88.0% and is now trading at $0.1711. View the best growth stocks for 2024 here. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPHW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVPHW CUSIPN/A CIK1742927 WebN/A Phone408-501-8881FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RVPHW) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.